BOSTON, Oct. 24, 2022 (GLOBE NEWSWIRE) — Block & Leviton is investigating Accelerate Diagnostics, Inc. AXDX for potential securities law violations. Investors who have lost money investing in Accelerate Diagnostics, Inc. should do so contact the company to learn more about how to make up for those losses. For more information, see https://www.blockleviton.com/cases/axdx.

Why is?

After the market close on October 21, 2022, Accelerate Diagnostics, Inc. announced that the U.S. Food and Drug Administration has received a request for the Company to cease marketing and distribution of its Accelerate Arc System and associated BC Kit for a discontinue certain diagnostic uses immediately.

Accelerate Diagnostics previously marketed the Accelerate Arc products as Class I devices and exempted them from 510(k) clearance requirements. The FDA recently informed the company that marketing the products in the United States requires 510(k) clearance.

Accelerate Diagnostics, Inc. shares fell about 9% in premarket trading and more than 40% in intraday trading on October 24, 2022.

Who is Eligible?

Anyone who has bought Accelerate Diagnostics, Inc. stock and lost money may be eligible, whether they have sold their investment or not. Investors should contact Block & Leviton for more information.

What does Block & Leviton do?

Block & Leviton is investigating whether the company has violated securities laws and may file a lawsuit to try to recover losses on behalf of investors who have lost money.

What should you do next?

If you’ve lost money on your investment, you should contact Block & Leviton to learn more about ours case website, by email at [email protected]or by calling (617) 398-5600.

Why should you contact Block & Leviton?

Many law firms have issued press releases in this regard; Most of these firms do not conduct securities class actions. Block & Leviton is a law firm that actually hears cases. We devote ourselves…